AMEDAMEDISYS INC

Nasdaq amedisys.com


$ 92.06 $ 0.00 (0 %)    

Monday, 29-Apr-2024 09:32:34 EDT
QQQ $ 432.68 $ -0.47 (-0.11 %)
DIA $ 383.51 $ 0.24 (0.06 %)
SPY $ 510.20 $ -0.06 (-0.01 %)
TLT $ 88.57 $ -0.09 (-0.1 %)
GLD $ 215.94 $ -0.11 (-0.05 %)
$ 91.79
$ 92.06
$ 0.00 x 0
$ 93.00 x 100
$ 92.06 - $ 92.06
$ 73.10 - $ 96.44
144,548
na
3.03B
$ 0.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-25-2024 03-31-2024 10-Q
2 02-22-2024 12-31-2023 10-K
3 10-25-2023 09-30-2023 10-Q
4 07-27-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-16-2023 12-31-2022 10-K
7 10-27-2022 09-30-2022 10-Q
8 07-28-2022 06-30-2022 10-Q
9 04-28-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 04-29-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 10-29-2020 09-30-2020 10-Q
16 07-29-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-19-2020 12-31-2019 10-K
19 10-30-2019 09-30-2019 10-Q
20 08-01-2019 06-30-2019 10-Q
21 05-01-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 10-30-2018 09-30-2018 10-Q
24 08-01-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 02-28-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 07-27-2017 06-30-2017 10-Q
29 05-03-2017 03-31-2017 10-Q
30 03-01-2017 12-31-2016 10-K
31 11-04-2016 09-30-2016 10-Q
32 08-03-2016 06-30-2016 10-Q
33 05-04-2016 03-31-2016 10-Q
34 03-10-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 07-29-2015 06-30-2015 10-Q
37 04-29-2015 03-31-2015 10-Q
38 03-04-2015 12-31-2014 10-K
39 10-29-2014 09-30-2014 10-Q
40 07-30-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-neutral-on-amedisys-maintains-101-price-target

Cantor Fitzgerald analyst Sarah James reiterates Amedisys (NASDAQ:AMED) with a Neutral and maintains $101 price target.

 amedisys-q1-2024-adj-eps-103-beats-102-estimate-sales-571400m-beat-565380m-estimate

Amedisys (NASDAQ:AMED) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $1.02 by 0.9...

 raymond-james-maintains-market-perform-on-amedisysto-market-perform

Raymond James analyst John Ransom maintains Amedisys (NASDAQ:AMED) from Market Perform to Market Perform.

 rbc-capital-maintains-outperform-on-amedisys-raises-price-target-to-100

RBC Capital analyst Ben Hendrix maintains Amedisys (NASDAQ:AMED) with a Outperform and raises the price target from $97 to $...

 amedisys-q4-2023-adj-eps-0940-misses-1030-estimate-sales-570800m-beat-567713m-estimate

Amedisys (NASDAQ:AMED) reported quarterly earnings of $0.940 per share which missed the analyst consensus estimate of $1.030 by...

 amedisys-q4-2023-adj-eps-094-misses-103-estimate-sales-57080m-beat-56771m-estimate

Amedisys (NASDAQ:AMED) reported quarterly earnings of $0.94 per share which missed the analyst consensus estimate of $1.03 by 8...

 amedisys-offers-molecular-testing-for-rapid-and-accurate-infection-diagnosis-in-collaboration-with-patient-choice-laboratories

Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering adva...

 amedisys-q3-adj-eps-098-misses-108-estimate-sales-55620m-miss-56127m-estimate

Amedisys (NASDAQ:AMED) reported quarterly earnings of $0.98 per share which missed the analyst consensus estimate of $1.08 by 9...

 cantor-fitzgerald-maintains-neutral-on-amedisys-raises-price-target-to-101

Cantor Fitzgerald analyst Sarah James maintains Amedisys (NASDAQ:AMED) with a Neutral and raises the price target from $100 ...

 td-cowen-maintains-market-perform-on-amedisys-raises-price-target-to-101

TD Cowen analyst Gary Taylor maintains Amedisys (NASDAQ:AMED) with a Market Perform and raises the price target from $84 to ...

 credit-suisse-reiterates-neutral-on-amedisys-maintains-101-price-target

Credit Suisse analyst Jonathan Yong reiterates Amedisys (NASDAQ:AMED) with a Neutral and maintains $101 price target.

 amedisys-q2-adj-eps-137-beats-109-estimate-sales-55300m-miss-56820m-estimate

Amedisys (NASDAQ:AMED) reported quarterly adj earnings of $1.37 per share which beat the analyst consensus estimate of $1.09 by...

 meta-platforms-to-rally-around-14-here-are-10-other-analyst-forecasts-for-thursday

Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi S...

 jefferies-downgrades-amedisys-to-hold-raises-price-target-to-101

Jefferies analyst Brian Tanquilut downgrades Amedisys (NASDAQ:AMED) from Buy to Hold and raises the price target from $98 to...

 analyst-ratings-for-amedisys
Analyst Ratings for Amedisys
06/27/2023 17:00:44

 benchmark-downgrades-amedisys-to-hold

Benchmark analyst Bill Sutherland downgrades Amedisys (NASDAQ:AMED) from Buy to Hold.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION